Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

KDventures

0.30 SEK

+1.88 %

Less than 1K followers

KDV B

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.88 %
-3.72 %
-16.19 %
-54.21 %
-62.90 %
-64.32 %
-82.23 %
-74.99 %
-98.97 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
196.21M SEK
Turnover
990.53K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30.4.
2026

Interim report Q1'26

12.5.
2026

General meeting '26

28.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Press release2/16/2026, 4:24 PM

DNB Carnegie Access: KDventures: Approaching decisive data – Q4 review

KDventures
Regulatory press release2/13/2026, 7:00 AM

Year-end Report - January-December 2025

KDventures
Regulatory press release2/12/2026, 2:45 PM

KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue

KDventures

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release2/10/2026, 12:41 PM

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer

KDventures
Press release2/6/2026, 7:05 AM

Karolinska Development’s portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement

KDventures
Regulatory press release1/28/2026, 3:45 PM

Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB

KDventures
Regulatory press release1/23/2026, 4:55 PM

Karolinska Development AB receives additional guarantee commitments in ongoing rights issue

KDventures
Press release1/21/2026, 3:24 PM

Karolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin

KDventures
Regulatory press release1/13/2026, 7:30 AM

The subscription period in Karolinska Development AB (publ)’s rights issue begins today

KDventures
Regulatory press release1/9/2026, 10:35 AM

Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue

KDventures
Regulatory press release1/8/2026, 10:00 AM

Karolinska Development’s Extraordinary General Meeting 2026

KDventures
Press release12/22/2025, 10:02 AM

DNB Carnegie Access: Karolinska Development: Portfolio company in a reverse takeover transaction

KDventures
Press release12/22/2025, 7:17 AM

Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development

KDventures
Press release12/11/2025, 7:28 AM

Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D

KDventures
Press release12/10/2025, 12:05 PM

Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia

KDventures
Press release12/10/2025, 8:25 AM

DNB Carnegie Access: Karolinska Development: Positive study data from AnaCardio

KDventures
Regulatory press release12/10/2025, 7:00 AM

Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01

KDventures
Regulatory press release12/2/2025, 9:23 AM

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

KDventures
Press release12/1/2025, 10:25 AM

DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee

KDventures
Regulatory press release12/1/2025, 7:00 AM

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB

KDventures
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.